Search
Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationaldiphtheriae* grown in another culture. … Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Betaprodine
go.drugbank.com/drugs/DB01473ExperimentalIllicitAn opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration. … It has been used in obstetrics, as pre-operative medication, for minor surgical procedures, and for dental procedures. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1067)
Lucanthone
go.drugbank.com/drugs/DB04967Investigational(From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Imazaquin
go.drugbank.com/drugs/DB04582ExperimentalCategories: Compounds used in a research, industrial, or household setting2,5-di-tert-butylhydroquinone
go.drugbank.com/drugs/DB04638ExperimentalCategories: Compounds used in a research, industrial, or household settingPSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
XL019
go.drugbank.com/drugs/DB05243InvestigationalAn IND for XL019 was filed by Exelixis in May 2007.
rGLP-1
go.drugbank.com/drugs/DB05433ExperimentalGLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.
Omburtamab
go.drugbank.com/drugs/DB15635Investigational[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. … [A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).